Startseite>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>Brilacidin (PMX 30063)

Brilacidin (PMX 30063) (Synonyms: PMX 30063)

Katalog-Nr.GC32238

Brilacidin (PMX 30063) (PMX 30063) ist ein antiinfektiÖses antimikrobielles Mittel mit MIC90s von 1 und 8 μ g/ml fÜr grampositive Bakterien Streptococcus pneumoniae und Streptococcus viridans und MIC90 von 8 und 4 μ g/ml fÜr Gram -negative Bakterien Haemophilus influenza und Pseudomonas aeruginosa.

Products are for research use only. Not for human use. We do not sell to patients.

Brilacidin (PMX 30063) Chemische Struktur

Cas No.: 1224095-98-0

Größe Preis Lagerbestand
1mg Please Inquire Please Inquire
5mg Please Inquire Please Inquire
10mg Please Inquire Please Inquire
20mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Brilacidin is a nonpeptidic anti-infective in a new class of defensin mimetics that is being developed for the treatment of eye infections.

Both Staphylococcus aureus (SA) and Staphylococcus epidermidis (SE) have the lowest minimum inhibitory concentrations among the bacterial groups. The MIC90s to Brilacidin for Streptococcus pneumonia (SP), Streptococcus viridians (SV), Moraxella (MS), Haemophilus influenza (HI), Pseudomonas aeruginosa (PA), and Serratia marcescens (SM) are 4, 32, 256, 32, 16, and 128-fold higher, respectively, than SA and SE. Brilacidin has Gram-positive in vitro activity; topical Brilacidin 0.5% is minimally irritating; and Brilacidin 0.5% was equally efficacious as Vancomycin (VAN) in a methicillin-resistant S. aureus (MRSA) keratitis model when the corneal epithelium is removed. Brilacidin acts primarily on the bacterial cell membrane by depolarization. Brilacidin is more potent for Gram-positive bacteria (except SV) than Gram-negative bacteria[1].

Brilacidin demonstrates dose-dependent ocular toxicity after 7 topical instillations (every 30 min for 3 h) in the NZW rabbit ocular toxicity model. Brilacidin 1% is determined to be Mildly Irritating (23.0), Brilacidin 0.5% (6.5), and Brilacidin 0.25% (4.0) are determined to be Minimally Irritating, while Brilacidin 0.1% (2.0) and TBS (1.0) are determined to be Practically Nonirritating and 0.01% Brilacidin (0.5) is determined to be Nonirritating based on their Maximum mean total scores (MMTS) values[1].

[1]. Kowalski RP, et al. An Independent Evaluation of a Novel Peptide Mimetic, Brilacidin (PMX30063), for Ocular Anti-infective. J Ocul Pharmacol Ther. 2016 Jan-Feb;32(1):23-7.

Bewertungen

Review for Brilacidin (PMX 30063)

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Brilacidin (PMX 30063)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.